BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rydapt (Midostaurin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rydapt (Midostaurin)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT00819546-2843@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rydapt (Midostaurin): Phase 1 readout est. (NCT00819546)
DESCRIPTION:Rydapt (Midostaurin)\, phase 1\, Acute Myeloid Leukemia.\nStudy
 : RAD001 in Combination With PKC412 in Patients With Relapsed\, Refractory
  or Poor Prognosis AML or MDS\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/midostaurin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT00819546
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06313437-2843@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20270302
DTEND;VALUE=DATE:20270303
SUMMARY:Rydapt (Midostaurin): Phase 1 readout est. (NCT06313437)
DESCRIPTION:Rydapt (Midostaurin)\, phase 1\, Acute Myeloid Leukemia.\nStudy
 : Revumenib in Combination With 7+3 + Midostaurin in AML\nEstimated primar
 y completion: 2 March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/midostaurin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06313437
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04385290-2843@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Rydapt (Midostaurin): Phase 1/2 readout est. (NCT04385290)
DESCRIPTION:Rydapt (Midostaurin)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Sta
 ndard Therapy for Acute Myeloid Leukemia (MOSAIC)\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mi
 dostaurin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04385290
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726576-2843@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rydapt (Midostaurin): Phase 1/2 readout est. (NCT07726576)
DESCRIPTION:Rydapt (Midostaurin)\, phase 1/2\, Acute Myeloid Leukemia.\nStu
 dy: Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acu
 te Myeloid Leukemia\nEstimated primary completion: September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/midostaurin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07726576
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03591510-2843@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20290518
DTEND;VALUE=DATE:20290519
SUMMARY:Rydapt (Midostaurin): Phase 2 readout est. (NCT03591510)
DESCRIPTION:Rydapt (Midostaurin)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : A Global Study of Midostaurin in Combination With Chemotherapy to Evalua
 te Safety\, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Pat
 ients With FLT3 Mutated AML\nEstimated primary completion: 18 May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/midostaurin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03591510
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02115295-2843@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Rydapt (Midostaurin): Phase 2 readout est. (NCT02115295)
DESCRIPTION:Rydapt (Midostaurin)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : Cladribine\, Idarubicin\, Cytarabine\, and Venetoclax in Treating Patien
 ts With Acute Myeloid Leukemia\, High-Risk Myelodysplastic Syndrome\, or B
 lastic Phase Chronic Myeloid Leukemia\nEstimated primary completion: 31 Ma
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/midostaurin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02115
 295
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948122-2843@assetmemo.bio
DTSTAMP:20261121T004534Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Rydapt (Midostaurin): Phase 3 readout est. (NCT07948122)
DESCRIPTION:Rydapt (Midostaurin)\, phase 3\, Acute Myeloid Leukemia.\nStudy
 : Prospective Evaluation of Response to Treatment in Younger Adult Patient
 s (18-60 Years) With Acute Myeloid Leukemia (AML)\nEstimated primary compl
 etion: 31 December 2035. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/midostaurin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07948122
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
